Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG P
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
| Condition(s) | Diffuse Large B Cell Lymphoma (DLBCL) |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL). |
| Who can participate | Inclusion Criteria: 1. Men and women ≥ 18 years of age deemed eligible for treatment with full-dose Pola- R-CHP and possible treatment with glofitamab by the qualified investigator. 2. Histologic diagnosis of DLBCL and variants according to the WHO 201613 or WHO 202254 classification including DLBCL non-organ-specific (NOS), Germinal centre B-cell type, activated B-cell type, T-cell/histiocyte-rich large B-cell lymphoma, Epstein-Barr Virus (EBV) + DLBCL, Primary mediastinal/thymic large B-cell lymphoma, High grade B-cell lymphoma with myelocytomatosis oncogene (MYC) and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements, High grade B cell lymphoma NOS including lymphomas transformed from previously untreated indolent lymphomas. 3. Previously untreated DLBCL with the fo |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Health Network, Toronto |
| Locations | Toronto, Ontario, Canada; Toronto, Ontario, Canada; Montreal, Quebec, Canada |
| Start date | 2025-01-24 |
| NCT ID | NCT06050694 |
| Official listing | https://clinicaltrials.gov/study/NCT06050694 |